I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
C series
—
16.12.2024
(C/2024/7305)
Language of the case: Dutch
Applicants: Almirall BV, Almirall SA
Defendants: Infinity Pharma BV, Pharmaline BV
1.Does a directive-compliant interpretation of Paragraphs 18(5) and 40(3) of the Geneesmiddelenwet (Law on medicinal products), in the light of the provisions of Article 3(2) of the Medicinal Products Directive, (1) reconcile the fact that the assessment of one of the exceptions to the authorisation requirement laid down in national law is also based on a quantitative measure that has been concretised by a numerical criterion?
2.Are the national authorities free to subject a medicinal product that falls under Article 3(2) of the Medicinal Products Directive, whereby the authorisation requirements regulated in Articles 6 and 40 of the same directive do not apply, to a national authorisation requirement on the basis of a quantitative condition regulated by national law and concretised by a numerical criterion?
3.Is it relevant to the answer to Questions 1 and 2 whether the Medicinal Products Directive provides for full harmonisation for the parts relevant to this case and, if so, does it provide for full harmonisation?
4.To what extent is it relevant to the answers to Questions 1 and 2 that, according to the Dutch-language version, the exception set out in the second sentence of Article 40(2) of the Medicinal Products Directive applies ‘voor verstrekking in het klein’ (‘for supply at retail’) or, according to the English-, French- and Italian-language versions of the directive, appears to relate to a number of operations performed by the pharmacist in the context of retail?
—
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67).
ELI: http://data.europa.eu/eli/C/2024/7305/oj
ISSN 1977-091X (electronic edition)
—